<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01654809</url>
  </required_header>
  <id_info>
    <org_study_id>BJCDPC-1</org_study_id>
    <nct_id>NCT01654809</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of Split Influenza Virus Vaccine in Different Age Groups</brief_title>
  <official_title>Evaluation of Safety and Immunogenicity Among Different Age-groups Receiving Different Split Influenza Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Center for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Center for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the adverse reaction ratio and hemagglutination
      inhibition (HI) antibody positive rate, Geometric mean titer (GMT) of three brands split
      influenza virus vaccine in different population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational Objectives:

      To describe the safety of evaluated vaccine, given in the two-dose schedule in accordance
      with the Package Insert, in children aged ≥ 6 months to ≤ 36 months,6th to 12th birthday and
      ≥ 60th birthday.

      To describe the immunogenicity of evaluated vaccine, given in the two-dose schedule in
      accordance with the Package Insert, in children aged ≥ 6 months to ≤ 36 months, 6th to 12th
      birthday and ≥ 60rd birthday.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the immunogenicity of evaluated vaccine</measure>
    <time_frame>6 months</time_frame>
    <description>The immunologic equivalence of 7days after vaccination of influenza virus vaccine was measured in terms of GMTs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the safety</measure>
    <time_frame>4 months</time_frame>
    <description>The incidence of adverse events was analyzed statistically</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">900</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>evaluated vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>imported compared vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>domestic compared vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>evaluated vaccine</intervention_name>
    <description>0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)</description>
    <arm_group_label>evaluated vaccine</arm_group_label>
    <arm_group_label>imported compared vaccine</arm_group_label>
    <arm_group_label>domestic compared vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>imported compared vaccine</intervention_name>
    <description>0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)</description>
    <arm_group_label>evaluated vaccine</arm_group_label>
    <arm_group_label>imported compared vaccine</arm_group_label>
    <arm_group_label>domestic compared vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>domestic compared vaccine</intervention_name>
    <description>0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)</description>
    <arm_group_label>evaluated vaccine</arm_group_label>
    <arm_group_label>imported compared vaccine</arm_group_label>
    <arm_group_label>domestic compared vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  participants were enrolled (toddlers: 6 months to 3 years; school-aged children: 6 to
             12 years and older adults: ≥60 years）

          -  Eligible participants were generally healthy or had stable chronic medical conditions
             (for older adults only)

        Exclusion Criteria:

          -  History of allergic reaction to any component of the study vaccines or previous
             influenza vaccine

          -  History of systemic hypersensitivity to hens' eggs

          -  History of Guillain Barré syndrome following administration of any influenza vaccine

          -  Any immunodeficient or immunocompromised conditions

          -  Receipt of cytotoxic or immunosuppressive drugs within the past 6 months

          -  Receipt of blood-derived product within the past 3 months

          -  Receipt of any vaccine within one month prior to study entry with exception of
             paediatric routine vaccination

          -  Receipt of non-study 2010-2011 seasonal TIV

          -  Participation in any other study with a non-approved drug during the study

          -  Acute febrile disease and other self-limiting illness were the temporary exclusion
             criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nianmin Shi, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Chaoyang District Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanhe Centre for Disease Control and Prevention</name>
      <address>
        <city>Langfang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiuyuan Center for Disease Control and Prevention</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2012</study_first_submitted>
  <study_first_submitted_qc>July 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2012</study_first_posted>
  <last_update_submitted>September 30, 2012</last_update_submitted>
  <last_update_submitted_qc>September 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

